108 related articles for article (PubMed ID: 8608539)
1. Urinary basic fetoprotein in the diagnosis and follow-up of patients with urothelial carcinoma.
Kigure T; Wakayama Y; Satoh Y; Fujieda N; Yoshida K; Harada T
Cancer; 1996 Apr; 77(8):1529-34. PubMed ID: 8608539
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
3. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma.
Yao WJ; Chang CJ; Chan SH; Chow NH; Cheng HL; Tzai TS; Lin SN
Anticancer Res; 1995; 15(6B):2819-23. PubMed ID: 8669871
[TBL] [Abstract][Full Text] [Related]
4. [Urinary tumor marker for urothelial cancer].
Ohtani M; Iwasaki A; Shiraiwa H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
[TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer].
Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K
Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195
[TBL] [Abstract][Full Text] [Related]
6. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
7. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies].
Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y
Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231
[TBL] [Abstract][Full Text] [Related]
8. [Clinical studies on the measurement of urinary tissue polypeptide antigen (TPA) levels using Prolifigen TPA kit "Daiichi"-II in urothelial cancers].
Ohmori H; Ohashi T; Aso Y; Kumamoto Y; Hisazumi H; Shiraiwa Y; Kurita T; Shimazaki J; Ohkawa T; Ogawa H
Hinyokika Kiyo; 1988 Dec; 34(12):2101-10. PubMed ID: 3071123
[TBL] [Abstract][Full Text] [Related]
9. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation on an enzyme immunoassay kit for basic fetoprotein (BFP). (1) Clinical usefulness of BFP].
Ishii M; Hattori N; Kato T; Mochizuki M; Kamidono S; Sawabu N; Kawada Y; Kawai T; Abe O; Ohkura H
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2107-13. PubMed ID: 2456039
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
[TBL] [Abstract][Full Text] [Related]
13. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
[TBL] [Abstract][Full Text] [Related]
14. The molecular signature for urothelial carcinoma of the upper urinary tract.
Ho CL; Tzai TS; Chen JC; Tsai HW; Cheng HL; Eisenberger CF; Chow NH
J Urol; 2008 Mar; 179(3):1155-9. PubMed ID: 18206169
[TBL] [Abstract][Full Text] [Related]
15. Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia.
Lane Z; Epstein JI
Am J Surg Pathol; 2008 May; 32(5):758-64. PubMed ID: 18379418
[TBL] [Abstract][Full Text] [Related]
16. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications.
Cheng L; Neumann RM; Bostwick DG
Cancer; 1999 Nov; 86(10):2102-8. PubMed ID: 10570438
[TBL] [Abstract][Full Text] [Related]
17. [Significance of urinary nuclear matrix protein 22 in diagnosis of transitional cell carcinoma of urinary tract].
Shao Y; Zhuang J; Xu SX; Liu DY
Ai Zheng; 2002 Sep; 21(9):1005-7. PubMed ID: 12508552
[TBL] [Abstract][Full Text] [Related]
18. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma.
Luo B; Li W; Deng CH; Zheng FF; Sun XZ; Wang DH; Dai YP
Cancer Genet Cytogenet; 2009 Mar; 189(2):93-7. PubMed ID: 19215789
[TBL] [Abstract][Full Text] [Related]
19. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens.
Moatamed NA; Rao JY; Alexanian S; Cobarrubias M; Levin M; Lu D; Apple SK
Cancer Cytopathol; 2013 Jun; 121(6):320-8. PubMed ID: 23364848
[TBL] [Abstract][Full Text] [Related]
20. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
